BS_G9XE3N9T
pilocytic astrocytoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- pilocytic astrocytoma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- pilocytic astrocytoma
- overall_survival_months
- 18.823915900131404
- age_years
- 4.614
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- KRAS_SIGNALING_DN+0.332
- MYOGENESIS+0.262
- APICAL_SURFACE+0.124
- UV_RESPONSE_DN+0.096
- PANCREAS_BETA_CELLS+0.068
- ESTROGEN_RESPONSE_LATE+0.032
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.030
- ESTROGEN_RESPONSE_EARLY+0.022
- HEME_METABOLISM+0.019
- XENOBIOTIC_METABOLISM+0.010
Top 10 suppressed
- MYC_TARGETS_V2-0.604
- E2F_TARGETS-0.595
- MYC_TARGETS_V1-0.588
- G2M_CHECKPOINT-0.565
- DNA_REPAIR-0.424
- ANGIOGENESIS-0.379
- TNFA_SIGNALING_VIA_NFKB-0.379
- TGF_BETA_SIGNALING-0.356
- UNFOLDED_PROTEIN_RESPONSE-0.352
- OXIDATIVE_PHOSPHORYLATION-0.326
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
1 twin match this tumor's tissue · 9 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MDT-AP-0810 | Med | Medulloblastoma | 0.945 |
| 2 | BS_SFKZSJN1 | low-grade glioma | — | 0.940 |
| 3 | BS_92VDQ0NE | Ganglioglioma | — | 0.906 |
| 4 | SRR657891 | GTEX | — | 0.906 |
| 5 | BS_063ERW0R | pilocytic astrocytoma | — | 0.900 |
| 6 | BS_QV51J756 | Ganglioglioma | — | 0.897 |
| 7 | BS_ME3HKN2C | Ganglioglioma | — | 0.897 |
| 8 | BS_CQSAJ7BF | DNET | — | 0.893 |
| 9 | BS_T2QPMZCM | low-grade glioma | — | 0.891 |
| 10 | BS_TMTV769C | low-grade glioma | — | 0.891 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 11 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| KRAS_SIGNALING_DN | 0.332 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.262 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.124 | Temsirolimus | — uncovered |
| UV_RESPONSE_DN | 0.096 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.068 | Cobimetinib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.032 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.030 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.022 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.019 | Temsirolimus | — uncovered |
| XENOBIOTIC_METABOLISM | 0.010 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.004 | Inavolisib | — uncovered |